Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.
about
Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?Recent update in HIV vaccine developmentConformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1The evolution within usAntibody responses to envelope glycoproteins in HIV-1 infectionPatterns of HIV/SIV Prevention and Control by Passive Antibody ImmunizationTargeting host-derived glycans on enveloped viruses for antibody-based vaccine designHIV-1 gp120 as a therapeutic target: navigating a moving labyrinthHIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimersSurvivors Remorse: antibody-mediated protection against HIV-1.Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV InfectionPredicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.Early antibody therapy can induce long-lasting immunity to SHIVAntibody 10-1074 suppresses viremia in HIV-1-infected individualsHIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus.Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.Antibodies for prevention of mother-to-child transmission of HIV-1Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-DependentIncomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal AntibodiesA New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection CohortBroadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates.Animal models in HIV-1 protection and therapyProtection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in MacaquesBreakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising.Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.Optimal Sequential Immunization Can Focus Antibody Responses against Diversity Loss and Distraction.Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies
P2860
Q26765043-F0997C4B-BA67-4905-B424-59A9729F41B0Q26766628-C1FE167E-0567-401D-B13F-E1F18E238011Q26782237-536EA2D4-E31C-4CBD-A296-A4DB31CB7D5CQ26801603-7047D003-AA6F-4988-B231-5C590ADF7D69Q26991572-702F2276-6E66-4681-B823-3DF2438480F6Q28068018-D608FB70-573A-46BD-B83B-8B3764CA95F2Q28084672-94C2D60C-E26B-432C-84AF-B3C2E1100130Q28086826-773B2510-F4C8-4F01-8236-3B5A8B71BEC4Q28647225-4342BFC7-1B6C-4ECE-B17E-30A1C6C1E7F0Q30238730-C330DA79-B40E-421E-90AF-25DA9DB903DDQ33620546-7FA4FF16-0A7D-4633-BF09-25458269F9B1Q33638320-F5781880-EBE4-488A-8848-C3C1FB5129DDQ33762877-4DD08446-B4A0-4C40-8BB1-010B9AF37375Q33786443-7A278C49-90D0-4187-B18B-A5736BF4AE49Q34531858-6E126095-8DCB-4AE7-AF65-A5D70A44B1B1Q34550046-3BCA2332-DD82-43F7-AFA9-905504CA7A32Q34594036-1450A905-1F21-4E53-9E64-CFAE1DE8E08BQ35069151-F32A9428-8FA3-4B32-BFE3-877FF00F9D02Q35076711-8758034E-8665-49B2-9F55-800C4F08FB31Q35545292-EEEC6AD5-4DC8-4616-941D-9A0DDB46BA46Q35619402-84211782-DBB4-42CB-A268-BC62BCD4A79DQ35686912-F7E76097-DB23-450E-B481-854A5116044FQ35743897-40397191-8B87-4BE2-AB0C-6B0276302CF3Q35827024-AA48EDE3-CBA7-4C3A-839D-259DF60C883AQ35894094-91CAE534-9E20-461C-B0C8-2925C1FC6541Q35914292-98F5ECD0-890C-4FF9-B326-0746EC32434CQ35914306-2728BE41-0C35-46BA-B858-1C318ABC78AEQ35920037-87FD807E-7D5A-4EFD-87A8-091AA1A019C3Q35974961-087E87DD-0D49-4B51-9CBF-12B94C43A744Q36008380-EFBAC04D-C878-4D71-B4E8-EBA3C69BAA76Q36079024-5BA33007-D73C-4D1D-B433-188127AA8556Q36086357-6A02CDE5-CEC9-412F-A7DE-1B732082F38DQ36112751-DC649189-E1BE-41D3-A51B-9DB80F59E6A8Q36263769-5C9B066A-AEF3-44EB-98D4-F6B3EE0049C4Q36290038-19CDC8B0-C90C-49A5-BE55-3442B46116E5Q36303368-E76A1FB9-07C0-437A-9E0D-8F78FDB39391Q36334359-C2E45580-89C6-4D63-9922-BEEC2C6EF36FQ36345558-89E937D7-8886-4E5D-9233-B03E49DC467EQ36515149-4AD2FC3D-C8A8-45DC-B595-FD5D81E22029Q36531018-E9180D9B-8EE4-4805-A81F-91BC3FC67460
P2860
Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Passive transfer of modest tit ...... ck SHIV infection in macaques.
@ast
Passive transfer of modest tit ...... ck SHIV infection in macaques.
@en
Passive transfer of modest tit ...... ck SHIV infection in macaques.
@nl
type
label
Passive transfer of modest tit ...... ck SHIV infection in macaques.
@ast
Passive transfer of modest tit ...... ck SHIV infection in macaques.
@en
Passive transfer of modest tit ...... ck SHIV infection in macaques.
@nl
prefLabel
Passive transfer of modest tit ...... ck SHIV infection in macaques.
@ast
Passive transfer of modest tit ...... ck SHIV infection in macaques.
@en
Passive transfer of modest tit ...... ck SHIV infection in macaques.
@nl
P2093
P2860
P50
P356
P1476
Passive transfer of modest tit ...... ck SHIV infection in macaques.
@en
P2093
Alicia Buckler-White
Brian Moldt
Dennis R Burton
Florian Klein
Hugo Mouquet
Malcolm A Martin
Martha C Nason
Masashi Shingai
Michael A Eckhaus
Olivia K Donau
P2860
P304
P356
10.1084/JEM.20132494
P407
P50
P577
2014-08-25T00:00:00Z